Biopharmaceutical medicines and therapies that use extracts from natural sources are at the leading edge of medical research.
Scientus Pharma., is developing proprietary technologies and pharmaceuticals created from the many therapeutic properties of cannabinoids.
Available research shows the 85 active compounds already isolated from cannabinoids may be useful in therapies ranging from cancer and bacterial infections, neurological and psychological problems, diabetes and pain reduction, to suppressing immune system response and stimulating bone growth.
Scientus is a vertically-integrated biopharmaceutical Licensed Dealer under the Narcotics Control Regulations of Canada with a focus on developing and commercializing pharmaceutical-grade cannabinoid derivative products. Being one of a limited number of Licensed Dealers in Canada authorized to handle cannabinoid products, Scientus has the ability to wholesale buy process and sell cannabinoid derivatives, from and to Licensed Producers, as well as international markets.
The Scientus facility is a sterile GMP-compliant 45,000 square foot facility located in the Greater Toronto Area and the company has access to a state-of-the-art R&D laboratory at University Health Network (UHN).
The management team and advisory boards have deep experience in the life sciences, drug development, clinical practice and product commercialization processes through their work at top tier organizations including some of the best known Life Sciences companies.
With its patent pending extraction and processing methods Scientus can produce continuous, consistent batch profiles (a key criteria in formulating pharma-grade derivative products). The Company's products will be dispensed in a range of dosing forms, all providing standard measured doses for reliable and consistent delivery of its therapeutic formulations.
Har Grover, Executive Chairman
Har Grover is an entrepreneur, investor, senior executive and strategist with over 30 years of experience in healthcare, life sciences and technology. He has worked with growth companies at all stages, from start-up to commercialization, to going public and growing through the $1 billion revenue mark. Har has helped companies enter new markets both in Canada and internationally - organically and through M&A, strategic alliances, and joint ventures.
He is the Co-Founder of CannScience Innovations and founder and managing director of Nucleus GC, a professional services and investment company in Toronto specializing in life sciences markets.
Har has served on several corporate and non-profit boards including: Chair of Armour Therapeutics, Chair of Crohn's and Colitis Canada, Board Director of Medworxx, Board Director of MedcannAccess. Har has an undergraduate degree in life sciences, and a MBA. He obtained professional CMC and ICD.D designations.
Trevor Folk, President and CEO
Trevor Folk is an operator and entrepreneur whose background is entirely focused on the operation of businesses in highly regulated sectors or industries where credentials, documentation, good governance and reporting are essential to daily existence. He has deep experience in capital markets, and the management of public companies.
He is Co-Founder of Hydrx Farms Ltd. located in the greater Toronto Area, specializing in the manufacturing, processing, and destruction of controlled substances. He was also the founder, CEO and director of a Toronto Stock Exchange listed oil & gas company based in Calgary, Alberta. Prior to this he was a director and the president of a Toronto-based brokerage firm licensed under the Ontario Securities Commission and other respective provinces as an Investment Fund Manager, Investment Counsel & Portfolio Manager, and Commodity Trading Manager from 2003 to 2011.
Trevor is a director of Avro Capital based in Vancouver. Avro Capital Partners is an independent investment and advisory firm. The investment portfolio and activity is predominantly focused on real estate and the life sciences and, beginning 2016, the seniors' living and medical office sectors.
Rav Grover, Executive Vice President and CFO
Rav Grover is a chartered accountant with significant experience in business advisory and business development, having worked in this capacity with a number of private and public companies over the last 25 years. He has been the lead M&A advisor on numerous transactions, structured a variety of debt instruments and equity raises, reverse takeovers and initial public offerings and advised on an array of tax structures.
He is Co-Founder of CannScience Innovations Inc. and currently also serves on several corporate boards and advisory boards.
Phillip A. Hemans, Executive Vice President and CCO
Phil Hemans is a chartered accountant, experienced executive and proven entrepreneur.
During his career he has served executive roles as COO of a leading wealth management company, CFO as well partner with a TSE member firm, and CEO of an integrated manufacturer of automotive parts.
He is Co-Founder of CannScience Innovations Inc. Over his career, he has led major business reorganizations, managed M&A transactions and helped raise capital for both private and public companies. This included structured finance transactions, equity and debt transactions, reverse takeovers and initial public offerings.
Phillip has an undergraduate degree in finance and is a Chartered Professional Accountant and Chartered Accountant.
Dr. Lakshmi Kotra CSO
Dr. Lakshmi P. Kotra is the Director at the Center for Molecular Design and Preformulations at UHN, a Senior Scientist at University Health Network (UHN), and Associate Professor of Medicinal Chemistry at University of Toronto.
He is Co-Founder of CannScience Innovations Inc. and has authored and co-authored over 100 publications including peer-reviewed scientific manuscripts, expert review articles and book chapters. He is the holder of several biomedical patents and has been a featured speaker at nearly 100 conferences around the world. Dr. Kotra has extensive experience in drug discovery research, and development in several therapeutic areas. Dr. Kotra teaches medicinal chemistry, and latest trends in drugs and biologics, including medical cannabinoids at the Leslie Dan Faculty of Pharmacy, University of Toronto.
Dr. Kotra is a recipient of several awards including the Premier's Research Excellence Award from the Province of Ontario, Rx&D Health Research Foundation Research Career award and the GlaxoSmithKline-Canadian Society for Pharmaceutical Sciences Young Investigator Award.
Dr. Kotra received his Ph.D. in pharmacy (medicinal chemistry) from the University of Georgia and postdoctoral training in the Department of Chemistry, Wayne State University.
Dr. Hance Clarke, Chief Medical Officer
Dr. Clarke is the Director of Pain Services and the Medical Director of the Pain Research Unit at the Toronto General Hospital. After his medical doctor (MD) and anesthesia subspecialty training in Toronto he received his PhD from the Institute of Medical Sciences at the University of Toronto and is a member of the Royal College Clinician Scientist Program.
His research interests identifying novel acute pain treatments following major surgery, identifying the factors involved in the transition of acute postsurgical pain to chronic pain and identifying risk factors associated with continued opioid use and poor health related quality of life after major surgery. He has further subspecialty training in Hyperbaric Medicine and Interventional Chronic Pain Management. Dr. Clarke was recently awarded the 2016 Early Career Award from the Canadian Pain Society and is recognized nationally and internationally for his research productivity and improvements to patient care such as the development of his novel Transitional Pain Program.
Eleanor N. Fish, Ph.D.
Dr. Fish is a Canada Research Chair in Women's Health & Immunobiology, Professor of Immunology at the University of Toronto and a Senior Scientist at the University Health Network in Toronto, Canada. Dr. Fish is a world-renowned immunologist and arthritis researcher, with a proven track record in basic and translational research for the development of various immunotherapeutics and diagnostic markers, including establishing interferon treatment protocols for the treatment of SARS, flu and Ebola virus infections.
Barry Greenberg, Ph.D.
Dr. Greenberg currently the Director, Neuroscience Drug Discovery and Development at University Health Network (Toronto). He has held a series of positions internationally in the US, Sweden and Canada within the biotechnology and pharmaceutical industries. Dr. Greenberg was the leader of a drug discovery project at AstraZeneca through lead optimization. Prior to moving to Toronto, he was Senior Director of Pharmacology at Neurochem. Dr. Greenberg has several decades of experience in drug development and clinical trials, in neurosciences.
Atul Humar, M.Sc., M.D.
Dr. Humar is the Director of the UHN Multi-Organ Transplant Program, and the University of Toronto Transplant Institute. Dr Humar received his medical degree from the University of Ottawa, and completed his clinical and research training in infectious diseases and Transplantation in Toronto and Boston. Dr. Humar's research interests are in virology with a focus on herpes virus infections post-transplant. He has received numerous honors and awards including Canada's Top 40 under 40 as well as several research awards.
Orlando Hung, B.Pharm., M.D.
Dr. Hung is an anesthesiologist, and specializes in pain management at Queen Elizabeth II Health Sciences Center in Halifax, NS, Canada, and a professor of Pharmacology and Anesthesiology, at Dalhousie University. Dr. Hung focuses on airway management, clinical pharmacology and drug delivery systems. Dr. Hung is responsible for the development of a number of innovative drug delivery systems and medical devices, especially for the delivery of narcotics and pain medications.
Donald F. Weaver, M.D., Ph.D.
Dr. Weaver is a Senior Scientist and Director of Krembil Research Institute at University Health Network, and a professor of Pharmacy, Chemistry and Medicine at University of Toronto. Dr. Weaver research includes drug design strategies to a variety of disorders, including Alzheimer's disease (AD), protein misfolding dementia (tauopathies), epilepsy and stroke. Dr. Weaver is also a neurologist, and practices in the Epilepsy Clinic at Toronto Western Hospital.
Developing high quality, safe and effective medications requires a team of people with expertise in the sciences and a commitment to global standards.
In 2014, Scientus (known as CannScience at the time) signed an agreement with University Health Network,Canada's premier network of teaching and research hospitals, to work together on the investigation and development of phytocannabinoids medicines. This agreement gives Scientus access to multiple world-class research facilities including the Centre for Molecular Design and Preformulations (CMDP), located in the MaRS Centre in the heart of Toronto, Canada.
The endocannabinoid system is a group of receptors and transmitters in the brain and nervous system that regulate many physiological and psychological processes in the human body. In medical trials of new drugs, human safety is the primary concern and each new product must show at what dosage its use becomes fatal. The advantage of cannabinoid medicines is that they have no known fatal dose.
Producing effective therapies also requires the delivery of medicines in standardized and metered concentrations. Scientus and its partners are committed to ensuring the highest global standards for our cannabinoid medicines.
Scientus has a wholly owned and operated 45,000 sq.ft. facility, 45 minutes from downtown Toronto. The facility provides a flexible pharmaceutical platform and is in compliance with quality and regulatory requirements of Health Canada. With its patent pending extraction and processing methods HydRx can produce continuous, consistent batch profiles (a key criteria in formulating pharma-grade derivative products).